Bacterial Infections

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1325-1345

  Leather, Helen L ^a,b   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Bacterial infections; Bacterial virulence factors; Biology of bacterial pathogens; Compromised host defenses; Fever following resolution of neutropenia; Mechanisms of antibiotic resistance; Patient management of neutropenia; Targets for various antibiotics

Indexed keywords

EID: 78649967890     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch88     Document Type: Chapter

References (189)

1. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat 2006; 9: 142-56.
2. Strausburgh LJ, Siegel JD, Weinstein RA. Preventing transmission of multidrug-resistant bacteria in health care settings: a tale of two guidelines. Clin Infect Dis 2006; 42: 828-35.
3. Garner JS. Guideline for isolation precautions in hospitals. The hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 1996; 17: 53-80.
4. Siegel JD, Rhinehart E, Jackson M et al. Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organsims in healthcare settings. http:www.cdc. gov/ncidod/pdf/ar/mdroGuideline2006.pdf (accessed July 6, 2007).
5. Craig M, Cumpston A, Hobbs GR et al. The clinical impact of antibiotic prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007; 39: 477-82.
6. Dykewicz CA, Jaffe HW, Kaplan JE, in collaboration with the Guidelines Working Group Members from the CDC, the Infectious Diseases Society of America and the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 659-737.
7. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
8. Bow EJ, Loewen R, Cheang MS et al. Cytotoxic therapy induced d-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997; 15: 2254-61.
9. Junghanss C, Marr KA, Carter RA et al. Incidence and outcome of bacterial and fungal infections after nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 515-20.
10. Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-5.
11. Hori A, Kami M, Kim SW et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 65-72.
12. Crippa F, Holmberg L, Carter RA et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 281-9.
13. Atkinson K, Storb R, Prentice RL et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53: 720-31.
14. Ochs L, Shu XO, Miller J et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979-86.
15. Collin BA, Leather HL, Wingard JR et al. Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947-53.
16. Oliveira AL, de Souza M, Carvalho-Dias VM et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007; 39: 775-81.
17. Wisplinghoff H, Seifert H, Wenzel R et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
18. Villablanca JG, Steiner M, Kersey J et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 1990; 5: 387-93.
19. Steiner M, Villablanca J, Kersey J et al. Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 1993; 42: 354-8.
20. Gassas A, Grant R, Richardson S et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol 2004; 22: 1222-7.
21. Classen DC, Burke JP, Ford CD et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990; 89: 441-6.
22. Marron A, Carratala J, Gonzalez-Barca E et al. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31: 1126-30.
23. Prabhu RM, Piper KE, Litzow MR et al. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005; 24: 832-8.
24. de Pauw BE, Donnelly JP, de Witte T et al. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1991; 5: 179-82.
25. Wang CC, Mattson D, Wald A. Corynebacterium jeikeium bacteremia in bone marrow transplant patients with Hickman catheters. Bone Marrow Transplant 2001; 27: 445-9.
26. Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987; 59: 844-9.
27. Gussack GS, Burson JG, Hudgins P et al. Sinusitis in the bone marrow transplant patient -diagnosis and management. Am J Rhinol 1995; 9: 31-5.
28. Deutsch JH, Hudgins PA, Siegel JL et al. The paranasal sinuses of patients with acute graftversus- host disease. Am J Neuroradiol 1995; 16: 1287-91.
29. Almyroudis NG, Fuller A, Jakubowski A et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7: 11-17.
30. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter- related infections. Clin Infect Dis 2001; 32: 1249-72.
31. Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. Bone Marrow Transplant 1994; 14: 247-52.
32. Youssef S, Rodriguez G, Rolston KV et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine 2007; 86: 69-77.
33. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology and interpretation of results. Clin Infect Dis 1996; 23: 40-6.
34. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
35. Reller LB, Murray PR, MacLowry JD. Cumitech 1A, Blood cultures II. Coordinating editor Washington JA II. Washington, DC: American Society for Microbiology; 1982.
36. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
37. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
38. Mustafa MM, Carlson L, Tkaczerwki I et al. Comparative study of cefepime verus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001; 20: 362-9.
39. Chuang YY, Hung IJ, Yang CP et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002; 21: 203-9.
40. Harter C, Schulze B, Goldschmidt H et al. Piperacillin/ tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2006; 37: 373-9.
41. Biron P, Fuhrmann C, Cure H et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Chemother 1998; 42: 511-18.
42. Engervall P, Kalin M, Dornbusch K et al. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. J Chemother 1999; 11: 278-86.
43. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34: 989-95.
44. Bow EJ, Rotstein C, Noskin GA et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43: 447-59.
45. Raad II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization. A prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039-47.
46. Cherif H, Bjorkholm M, Engervall P et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.
47. Del Favero A, Menichetti F, Martino P et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-301.
48. Hess U, Bohme C, Rey K et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6: 402-9.
49. Feld R, DePauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-8.
50. Vandercam B, Gerain J, Humblet Y et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000; 79: 152-7.
51. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-42.
52. Paul M, Soares-Weiser K, Grozinsky S et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003(3): CD003038.
53. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176-89.
54. Bliziotis IA, Samonis G, Varkadas KZ et al. Effect of aminoglycoside and ß-lactam combination therapy versus ß-lactam monotherapy on the emergence of antimicrobial resistance: a metaanalysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-58.
55. Breen J, Ramphal R, Cometta A et al. Cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky JA, editor. Febrile Neutropenia. New York: Springer Verlag, 1997. pp. 63-75.
56. Owens RC, Owens CA, Holloway WJ. Reduction in vancomcyin (VANC) consumption in patients with fever and neutropenia. Infectious Disease Society of America Abstracts New Orleans, Abstract 458.
57. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162: 981-3.
58. Mimoz O, Leotard S, Jacolot A et al. Efficacies of imipenem, meropenem, cefepime and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamaseproducing strain of Enterobacter cloacae. Antimicrob Agents Chemother 2000; 44: 885-90.
59. Mebis J, Goossens H, Bruyneel P et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998; 12: 1627-9.
60. Winston DJ, Lazarus HM, Beveridge RA et al. Randomized double-blind multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001; 32: 381-90.
61. Giamarellou H, Bassaris HP, Petrikkos G et al. Monotherapy with intravenous followed by highdose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000; 44: 3264-71.
62. Bliziotis IA, Michalopoulos A, Kasiakou SF et al. Ciprofloxacin vs an aminoglycoside in combination with a ß-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clinic Proc 2005; 80: 1146-56.
63. Chatzinikolaou I, Abi-Said D, Bodey GP et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-9.
64. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
65. Paul M, Silbiger I, Grozinsky S et al. Beta lactam antibiotic monotherapy versus beta lactam aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006(1): CD003344.
66. Attal M, Schlaifer D, Rubie H et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. J Clin Oncol 1991; 9: 865-70.
67. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomzied controlled trials. J Antimicrob Chemother 2005; 55: 436-44.
68. Vardakas K, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005; 5: 431-9.
69. Jaksic B, Martinelli G, Pererz-Oteyza J et al. Effi- cacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607.
70. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulasenegative staphylococci. N Engl J Med 1989; 316: 927-31.
71. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44: 1-13.
72. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005(3): CD003914.
73. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-22.
74. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low risk febrile patients with neutropenia during cancer chemotherapy. New Engl J Med 1999; 341: 305-11.
75. Klastersky J, Paesmans M, Rubenstein EB et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifiying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-51.
76. Klastersky J, Paesmans M, Georgala A et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24: 4129-34.
77. Shenep JL, Flynn PM, Baker DK et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32: 36-43.
78. Vidal L, Paul M, Ben Dor I et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004(4): CD003992.
79. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
80. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001; 33: 210-19.
81. Zirakzhadel A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clinic Proc 2006; 81: 529-36.
82. Weigel LM, Clewell DB, Gill SR et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003; 302: 1569-71.
83. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant enterococcus among patients with cancer. Am J Infect Control 2006; 34: 534-6.
84. Weinstock DM, Conlon M, Iovino C et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007; 13: 615-21.
85. Dubberke ER, Hollands JM, Georgantopoulos P et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker?. Bone Marrow Transplant 2006; 38: 813-19.
86. Rolston KV, Jiang Y, Matar M. VRE fecal colonization/ infection in cancer patients. Bone Marrow Transplant 2007; 39: 567-8.
87. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a metaanalysis. Clin Infect Dis 2005; 41: 327-33.
88. Poutsiaka DD, Price LL, Ucuzian A et al. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 2007; 40: 63-70.
89. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-92.
90. Husni R, Hachem R, Hanna H et al. Risk factors for vancomycin-resistant enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002; 23: 102-3.
91. Fridkin SK, Edwards JR, Courval JM et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistantenterococci in 126 US adult intensive care units. Ann Intern Med 2001; 135: 175-83.
92. Sehulster L, Chinn RW. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 53: 1-42.
93. Diekma DJ, Edmond MB. Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 2007; 44: 1101-7.
94. Siegel JD, Rhinehart E, Jackson M et al. Management of multidrug-resistant organisms in healthcare settings, 2006. http://www.cdc.gov/ncidod/ dhqp/pdf/ar/mdroGuideline2006.pdf (accessed April 12, 2008).
95. Norris AH, Reilly JP, Edelstein PH et al. Chloramphenicol for the treatment of vancomycinresistant enterococcal infections. Clin Infect Dis 1995; 20: 1137-44.
96. Winston DJ, Emmanouilides C, Kroeber A et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000; 30: 790-7.
97. Linden PK, Moellering RC, Wood CA et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33: 1816-23.
98. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5: 121-5.
99. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003; 14: 795-801.
100. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-52.
101. Poutsiaka DD, Skiffington S, Miller KB et al. Daptomycin in the treatment of vancomycinresistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54: 567-71.
102. Malnick S, Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2002; 36: 1767-75.
103. Bartlett SG. Antibiotic-associated diarrhea. N Engl J Med 2001; 346: 334-9.
104. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
105. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007; 45: 222-7.
106. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain on Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
107. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
108. Pépin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
109. Wamy M, Pépin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
110. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90.
111. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk -four states, 2005. MMWR Morbid Mortal Wkly Rep 2005; 54: 1201-5.
112. Klein EJ, Boster DR, Stapp JR et al. Diarrhea etiology in a children's hospital emergency department: a prospective cohort study. Clin Infect Dis 2006; 43: 807-13.
113. Bilgrami S, Feingold JM, Dorsky D et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1039-42.
114. Avery R, Pohlman B, Adal K et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000; 25: 67-9.
115. Tomblyn M, Fordon L, Singhal S et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 2002; 30: 517-19.
116. Arango JI, Restrepo A, Schneider DL et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37: 517-21.
117. Teasley DG, Gerding DN, Olson MM et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet 1982; 2: 1043-6.
118. Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 72: 813-18.
119. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
120. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
121. Gorschluter M, Glasmacher A, Hahn C et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33: 786-91.
122. Louie TJ, Peppe J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderate severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-20.
123. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammoniaproducing species. Chemotherapy 2000; 46: 253-66.
124. Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421-7.
125. Musher DM, Logan N, Mehendiratta V et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59: 705-10.
126. Moellering RC, Graybill JR, McGowan JE, Corey L. Antimicrobial resistance prevention initiative -an update: proceedings of an expert panel on resistance. Am J Med 2007; 120: S4-25.
127. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentrations interpretative criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
128. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
129. Gorschluter M, Mey U, Strehl J et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005; 75: 1-13.
130. Davila ML. Neutropenic enterocolitis. Curr Opin Gastroenterol 2006; 22: 44-7.
131. Wingard JR, Dick JD, Charache P, Saral R. Antibiotic- resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob Agents Chemother 1986; 30: 435-9.
132. Lai KK, Melvin ZS, Menard MJ et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors and infection control. Infect Control Hosp Epidemiol 1997; 18: 628-32.
133. Mayfield JL, Leet T, Miller J et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 995-1000.
134. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for prevention of intravascular catheter- related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51: 1-29.
135. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 59: 359-69.
136. Hanna H, Benjamin R, Chatzinikolaou I et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 3163-71.
137. Rupp ME, Lisco SJ, Lipsett PA et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections. A randomized, controlled trial. Ann Intern Med 2005; 143: 570-80.
138. Lew MA, Kehoe K, Ritz J et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239-50.
139. Jansen J, Cromer M, Akard L, Black JR, Wheat LJ, Allen SD. Infection prevention in severely myelosuppressed patients. A comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med 1994; 96: 335-41.
140. Gafter-Gvili A, Fraser A, Paul M et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005(4): CD004386.
141. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95.
142. Sampi K, Maseki N, Hattori M. A conparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan To Kagaku Ryoho 1992; 19: 823-6.
143. Broun ER, Wheat JL, Kneebone PH et al. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 1994; 38: 576-9.
144. D'Antonio D, Iacone A, Fioritoni G et al. Antibacterial prophylaxis in granulocytopenic patients. A randomized study of ofloxacin versus norfloxacin. Current Therapeutic Research 1991; 50: 304-11.
145. Prevention of bacterial infection in neutropenic patients with hematologic malignanices. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Ann Intern Med 1991; 115: 7-12.
146. Fanci R, Leoni F, Bosi A et al. Chemoprophylaxis of bacterial infection in granulocytopenic patients with ciprofloxacin vs cisprofloxacin plus amoxicillin. J Chemother 1993; 5: 119-23.
147. Ford CD, Reilly W, Wood J et al. Oral antimicrobial prophylaxis in bone marrow transplant recipients: randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin. Antimicrob Agents Chemother 1998; 42: 1402-5.
148. Gomez-Martin C, Sola C, Hornedo J et al. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. J Clin Oncol 2000; 18: 2126-34.
149. Hidalgo M, Hornedo J, Lumbreras C et al. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother 1997; 41: 1175-7.
150. Jansen J, Cromer M, Akard L et al. Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med 1994; 96: 335-41.
151. Prentice HG, Hann IM, Nazareth B et al. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol 2001; 115: 46-52.
152. Gluckman E, Roudet C, Hirsch I et al. Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum non-absorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin). Chemotherapy 1991; 37(Suppl 1): 33-8.
153. Kern W, Kurrle E. Ofloxacin versus trimethoprimsulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection 1991; 19: 73-80.
154. Ruiz I, Fuentes I, Capdevila JA et al. Ofloxacin prophylaxis in preventing bacterial infection after autologous peripheral blood stem cell transplantation (A-PBSC). In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 2001. Washington, DC: American Society of Microbiology; 2001. p. 447.
155. Archimbaud E, Guyotat D, Maupas J et al. Pefloxacin and vancomycin vs gentamicin, colistin sulphate and vancomycin for the prevention of infections in granulocytopenic patients: a randomized double-blind study. Eur J Cancer 1991; 27: 174-8.
156. Reduction of fever and streptococcal bacteremia in granuclocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA 1994; 272: 1183-9.
157. Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-87.
158. von Baum H, Sigge A, Bommer S et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006; 58: 891-4.
159. Gafter-Gvili A, Paul M, Frasaer A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5-22.
160. Broun ER, Wheat JL, Kneebone PH, Sundblad K, Hromas RA, Tricot G. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 1994; 38: 576-9.
161. International Antimicrobial Therapy Group of the European Organization for Research and Treat ment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 1994; 272: 1183-9.
162. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
163. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-87.
164. Rotstein C, Mandell LA, Goldberg N. Fluooroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Opin Oncol 1997; 4: 2-7.
165. Cruciani M, Malena M, Bosco O et al. Reappraisal with meta-analysis of the addition of grampositive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21: 4127-37.
166. van de Wetering MD, de Witte MA, Kremer LC et al. Efficacy of oral prophylactic antibiotics in netropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005; 41: 1372-82.
167. Sullivan KM, Dahlberg S, Storb R et al. Infection prophylaxis with chronic graft-versus-host disease. Exp Hematol 1993; 1: 193.
168. Kulkarni S, Powers R, Treleaven J et al. Chronic graft versus host disease is associated with longterm risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683-6.
169. Dekker A, Bulley S, Beyene J et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-15.
170. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol 2006; 24: 3187-205.
171. Sonis ST, Lindquist L, Van Vugt A et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 1994; 54: 1135-8.
172. Housley RM, Morris CF, Boyle W et al. Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994; 94: 1764-77.
173. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-8.
174. Freytes CO, Ranatanatharathorn V, Taylor C et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 2004; 10: 8318-24.
175. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491-6.
176. Clift RA, Sanders JE, Thomas ED et al. Granulocyte transfusions for the prevention of infection in patients receiving bone marrow transplants. N Engl J Med 1978; 298: 1052-7.
177. Winston DJ, Ho WG, Young LS et al. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 1980; 68: 893-7.
178. Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000; 95: 3302-9.
179. Stanworth SJ, Massey E, Hyde C et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005(3): CD005339.
180. Oza A, Hallemeier C, Goodnough L et al. Granulocyte- colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 2006; 46: 14-23.
181. Sullivan KM, Kopecky J, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-12.
182. Sullivan KM, Storek J, Kopecky J et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44-53.
183. Graham-Pole J, Camitta B, Casper CJ et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 1988; 3: 559-66.
184. Petersen FB, Bowden RA, Thornquist M et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant 1987; 2: 141-7.
185. Winston D, Antin JH, Wolff SN et al. Multicenter, randomized, double-blind doses of intravenous immunoglobulin for the prevention of graft versus host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 187-91.
186. Wolff SN, Fay JW, Herzig RH et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993; 118: 937-42.
187. Bernard GR, Vincent JL, Laterre PF et al. Effi- cacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
188. Abraham E, Laterre PF, Garg R et al. Drotecogin alfa (activated) for adults with severe sepsis and low risk for death. N Engl J Med 2005; 353: 1332-41.
189. Pastores SM, Shaw A, Williams MD et al. A safety evaluation of drotecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons learned in clinica research. Bone Marrow Transplant 2005; 36: 721-4.